Moloney Securities Asset Management LLC decreased its position in Chimerix, Inc. (NASDAQ:CMRX) by 77.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 28,500 shares of the biopharmaceutical company’s stock after selling 95,975 shares during the period. Moloney Securities Asset Management LLC owned approximately 0.06% of Chimerix worth $155,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Teza Capital Management LLC purchased a new position in shares of Chimerix during the first quarter valued at $135,000. American International Group Inc. increased its stake in shares of Chimerix by 7.1% in the first quarter. American International Group Inc. now owns 26,281 shares of the biopharmaceutical company’s stock valued at $168,000 after buying an additional 1,733 shares in the last quarter. Trexquant Investment LP bought a new stake in shares of Chimerix during the first quarter valued at approximately $226,000. Metropolitan Life Insurance Co. NY bought a new stake in shares of Chimerix during the first quarter valued at approximately $226,000. Finally, Nationwide Fund Advisors increased its stake in shares of Chimerix by 5.9% in the first quarter. Nationwide Fund Advisors now owns 35,573 shares of the biopharmaceutical company’s stock valued at $227,000 after buying an additional 1,977 shares in the last quarter. 64.98% of the stock is owned by institutional investors.
Shares of Chimerix, Inc. (CMRX) opened at 4.40 on Friday. Chimerix, Inc. has a 12-month low of $3.66 and a 12-month high of $6.64. The firm has a 50-day moving average price of $5.01 and a 200-day moving average price of $5.41. The firm’s market cap is $207.00 million.
Chimerix (NASDAQ:CMRX) last released its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.05. Chimerix had a negative net margin of 1,514.27% and a negative return on equity of 24.68%. The business had revenue of $0.68 million during the quarter, compared to analyst estimates of $1.28 million. Equities research analysts anticipate that Chimerix, Inc. will post ($1.63) EPS for the current year.
Several equities research analysts recently issued reports on CMRX shares. Cowen and Company reissued a “hold” rating and issued a $6.00 price objective on shares of Chimerix in a research note on Friday, April 28th. FBR & Co reaffirmed a “hold” rating and set a $7.00 price target on shares of Chimerix in a research note on Monday, May 1st. Zacks Investment Research downgraded Chimerix from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Finally, ValuEngine downgraded Chimerix from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $7.56.
About Chimerix
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
